Latest Hotspot

Akeso announced FDA's approval of their IND for AK117/Azacitidine combo treatment for Myelodysplastic Syndromes

8 October 2023
3 min read

Akeso, Inc. has made it known that their IND application for AK117, which pairs a revolutionary CD47 monoclonal antibody with azacitidine, has been approved by the U.S. FDA. This treatment is intended for patients who have just been diagnosed with high-risk myelodysplastic syndromes. The imminent research, identified as a double-blind, randomized, worldwide multicenter Phase II study, will be carried out in the U.S.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Akeso has engaged in thorough scientific exchanges and conversations with the FDA, based on AK117's impressive track record of efficacy and safety when used in conjunction with azacitidine in the treatment of newly diagnosed higher-risk MDS patients, as proven in prior research. Given the global demand from MDS patients, Akeso is confident that this study will accelerate the worldwide advancement of AK117.

"By granting us the luxury of time and space, we will steadfastly pursue a rigorous global approach in the investigation and progress of our groundbreaking therapies. For the good of a broader patient population, we will harness global resources to augment the success rate of AK117," declared Dr. Michelle Xia, who is the founder, Chairwoman, CEO, and President of Akeso.

Controlling anemia, a hallmark symptom of MDS, and limiting the necessity for blood transfusion are integral components of disease management. Unlike other anti-CD47 antibody drugs which reportedly exacerbate anemia in MDS patients by inducing RBC agglutination, AK117 eradicates RBC agglutination while simultaneously preserving full effectiveness of CD47 blockade on cancer cells. This leads to its superior antitumor efficacy and safety profile of AK117.

Previous research of AK117 used with azacitidine revealed encouraging results in MDS patients who were newly diagnosed with higher-risk. AK117 lessened anemia and the demands for transfusion in MDS patients, while revealing an outstanding safety profile and superb efficacy. Such outcomes position AK117 as an optimistic treatment choice for MDS patients across the globe.

It's worth noting that Akeso is unyielding in its progress of AK117 as a therapeutic aid used with various other agents like PD-1/CTLA-4 and PD-1/VEGF, in the treatment of numerous hematologic malignancies and solid tumors.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of October 5, 2023, there are 138 investigational drugs for the CD47 target, including 121 indications,124 R&D institutions involved, with related clinical trials reaching 238and as many as 11315 patents.

AK117, a unique product of Akeso, represents the future of humanized lgG4 anti-CD47 antibodies and it does not induce hemagglutination. By attaching itself to CD47 proteins found on cancer cells, AK117 interferes with the interaction between CD47 and SIRPα. This increases the capacity of phagocytes to consume cancer cells, thus staving off tumor growth. Ligufalimab getting to this point implies encouraging outcomes from the previous stages of its trials.

图形用户界面, 文本, 应用程序

描述已自动生成

Adcentrx Therapeutics starts Phase 1a/b trials of ADRX-0706, a new ADC targeting Nectin-4, for advanced solid tumors
Latest Hotspot
3 min read
Adcentrx Therapeutics starts Phase 1a/b trials of ADRX-0706, a new ADC targeting Nectin-4, for advanced solid tumors
8 October 2023
Adcentrx Therapeutics reports the initial dosing of a patient in the Phase 1a/b trial of ADRX-0706, an innovative ADC targeting Nectin-4, aimed to treat advanced solid tumors.
Read →
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
Latest Hotspot
3 min read
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
8 October 2023
Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.
Read →
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
Latest Hotspot
3 min read
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
8 October 2023
A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.
Read →
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
Latest Hotspot
3 min read
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
8 October 2023
Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.